ApoCell

ApoCell developed proprietary biomarker technologies for isolating and characterizing rare circulating cells (CTCs, CECs, stem cells) using liquid biopsy techniques, supporting over 140 clinical cancer drug trials. Its early proof-of-mechanism platforms enhanced drug candidate evaluation and patient stratification for oncology and diabetes clinical trials. The company established a significant presence in Europe (Leipzig, Germany) and collaborated closely with the Fraunhofer Institute (IZI) to further develop its technology for clinical applications. Its technologies focused on rare circulating cell isolation to enable earlier and more precise clinical decision-making in drug development, facilitating pharmacodynamic assessments, patient stratification, and dosing strategies.